U.S. Biochip Product & Services Market To Witness Increasing Revenue Growth During The Forecast Period 2020–2027


The growing development of drugs is expected to augment the growth of U.S. biochip product & services market. According to Pharmaceutical Research and Manufacturers of America, over 750 orphan drugs were approved in the U.S. in 2018, compared to over 600 in 2017. Also, a growing number of clinical trials is also expected to foster the growth of the market. According to the U.S. National Library of Medicine, the number of clinical trials conducted in the U.S. increased from 30,978 in 2018 to 32,523 in 2019. On the other hand, the high cost of the devices and services is expected to hinder the growth of the U.S. biochip product & services market. For example, the retail price of a single human biochip costs around US$ 400 to US$ 500.

Furthermore, the growing prevalence of cancer is again accelerating the growth of the market. According to the American Cancer Society, in 2019, there will be an estimated 1,762,450 new cancer cases diagnosed and 606,880 cancer deaths in the U.S.

Additionally, key players in the market are focused on adopting partnership or agreement strategies to expand their product portfolio. For example, in March 2020, MGI Tech Co., Ltd partnered with SkyWater Technology, a DMEA-accredited Category 1A Trusted Foundry, under which the latter will provide critical components used by MGI’s DNA sequencing system DNBSEQ-T7.

Read More: https://bit.ly/3jEsNsW

Comments

Popular posts from this blog

U.S. Meibomian Gland Dysfunction Market is growing rapidly with ThermaMEDx introducing a self-healing, disposable, pre-moistened, sterile cleaning eye-pad for use in treating the symptoms of dry eyes and meibomian gland dysfunction

Boston Sci Launched A New Device For Erectile Dysfunction Devices Market

Bakeable Trays Market Estimated To Develop At Cagr at 4.8% During Estimate Duration 2019-2027